IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL
Sun, Y-Q1,2; Wang, J.1,2; Jiang, Q.1,2; Xu, L-P1,2; Liu, D-H1,2; Zhang, X-H1,2; Liu, K-Y1,2; Huang, X-J1,2,3
刊名BONE MARROW TRANSPLANTATION
2015
DOI10.1038/bmt.2014.195
50期:1页:20-25
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]ACUTE LYMPHOBLASTIC-LEUKEMIA ; STEM-CELL TRANSPLANTATION ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; BONE-MARROW-TRANSPLANTATION ; SINGLE-CENTER ; REMISSION ; OUTCOMES ; RELAPSE ; MULTICENTER ; EXPERIENCE
英文摘要

Only 30% of high-risk adult ALL patients in their first complete remission (CR1) are able to receive an HLA-matched sibling stem cell transplant. The role of haploidentical hematopoietic SCT (haplo-HSCT) in post-remission therapy is not well established. Recently, we developed a novel protocol for unmanipulated haploidentical transplantation. In this study, we compared haplo-HSCT with conventional consolidation and maintenance chemotherapy in adult high-risk ALL patients. Between January 2000 and December 2012, 104 patients received conventional chemotherapy and 79 patients received haplo-HSCT. Patients who underwent haplo-HSCT had significantly improved 3-year OS (72.5% vs 26.6%; P < 0.001), 3-year disease-free survival (DFS) (63.9% vs 21.1%; P < 0.001) and 3-year relapse (18.7% vs 60.5%; P < 0.001) rates. The non-relapse mortality (NRM) rate was not different between patients treated with haplo-HSCT vs chemotherapy (19.2% vs 14.4%; P = 0.80). In multivariate analysis, the only factor associated with improved OS, better DFS and low risk of relapse was haplo-HSCT. The only factor associated with high NRM was enrollment before 2006. In conclusion, haplo-HSCT may be an option for adults with high-risk ALL in CR1 who do not have an HLA-matched donor.

语种英语
WOS记录号WOS:000347806800005
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59716
专题北京大学第二临床医学院_血液科
作者单位1.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
2.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
3.Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Sun, Y-Q,Wang, J.,Jiang, Q.,et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL[J]. BONE MARROW TRANSPLANTATION,2015,50(1):20-25.
APA Sun, Y-Q.,Wang, J..,Jiang, Q..,Xu, L-P.,Liu, D-H.,...&Huang, X-J.(2015).Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL.BONE MARROW TRANSPLANTATION,50(1),20-25.
MLA Sun, Y-Q,et al."Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL".BONE MARROW TRANSPLANTATION 50.1(2015):20-25.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, Y-Q]的文章
[Wang, J.]的文章
[Jiang, Q.]的文章
百度学术
百度学术中相似的文章
[Sun, Y-Q]的文章
[Wang, J.]的文章
[Jiang, Q.]的文章
必应学术
必应学术中相似的文章
[Sun, Y-Q]的文章
[Wang, J.]的文章
[Jiang, Q.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。